Cardiff Oncology, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
CRDF$0.80+5.3%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except par value)
| June 30,2026 | December 31,2025 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $9,197 | $17,470 |
| Short-term investments | 25,323 | 40,834 |
| Accounts receivable and unbilled receivable | 189 | 182 |
| Prepaid expenses and other current assets | 883 | 1,642 |
| Total current assets | 35,592 | 60,128 |
| Property and equipment, net | 450 | 578 |
| Operating lease right-of-use assets | 360 | 629 |
| Other assets | 927 | 549 |
| Total Assets | $37,329 | $61,884 |
| Liabilities and Stockholders’ Equity | ||
| Current liabilities: | ||
| Accounts payable | $3,986 | $8,087 |
| Accrued liabilities | 6,354 | 7,577 |
| Operating lease liabilities | 457 | 730 |
| Total current liabilities | 10,797 | 16,394 |
| Operating lease liabilities, net of current portion | — | 102 |
| Total Liabilities | 10,797 | 16,496 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value, 20,000 shares authorized; 277 designated as Series A Convertible Preferred Stock; 61 shares outstanding at June 30, 2026 and December 31, 2025 with liquidation preference of $1,129 and $1,117 at June 30, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.0001 par value, 150,000 shares authorized; 68,502 and 68,305 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 7 | 7 |
| Additional paid-in capital | 478,194 | 475,361 |
| Accumulated other comprehensive gain (loss) | (62) | 50 |
| Accumulated deficit | (451,607) | (430,030) |
| Total stockholders’ equity | 26,532 | 45,388 |
| Total liabilities and stockholders’ equity | $37,329 | $61,884 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.